Caricamento...
Favorable response to icotinib in a lung cancer patient with a special mutation at exon 19 of epidermal growth factor receptor
Many studies have illustrated that two types of mutation – deletions in exon 19 and a point mutation in exon 21 (L858R) – have been reported to comprise up to 90% of all activating epidermal growth factor receptor (EGFR) mutations. A point mutation at exon 19 is a rare mutation, and to date there ha...
Salvato in:
| Pubblicato in: | Thorac Cancer |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BlackWell Publishing Ltd
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4704356/ https://ncbi.nlm.nih.gov/pubmed/26767025 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12096 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|